

# 15<sup>th</sup> Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice and Post-MASCC

## Organizing Committee

### ***Institut Jules Bordet:***

A. Awada, N. Kotecki, P. Aftimos, M. Piccart

### ***BSMO:***

J. Collignon, H. Prenen, W. Lybaert, M. Ignatiadis, S. Rottey

### ***Post-MASCC:***

J. Klastersky, C. Fontaine

## Post-MASCC

### *Friday 3<sup>rd</sup> December 2021 Morning*

09.00 – 09.05	Introduction ( <b>C. Fontaine</b> , UZ Brussel)
09.05 – 09.25	Models of supportive care – <b>D. Hui</b> (USA)
09.25 – 09.50	The treatment of pain in Belgium: state of the art ( <b>C. Fontaine</b> )
09.50 – 10.10	Genetic and epigenetic role of muscle in cardiotoxicity and cancer-related fatigue ( <b>P.J. Lin</b> , USA)
10.10 – 10.35	Malnutrition in patients with cancer ( <b>E. De Waele</b> , UZ Brussel)
10.35 – 11.00	Rare cancer patients: unmet needs in supportive care ( <b>L. Gatellier</b> , Japan)
11.00 – 11.15	<i>News from the Industry</i>
11.15 – 11.40	Genetic counseling for hereditary cancer ( <b>C. Tamura</b> , Japan)
11.40 – 12.05	Febrile neutropenia: most recent guidelines – <b>J. Klastersky</b> (IJB)
12.05 – 12.30	Covid – 19 and supportive care ( <b>F. Ashbury</b> , USA)
12.30 – 12.35	Conclusions ( <b>J. Klastersky</b> )

# 15<sup>th</sup> BSMO-Bordet symposium on the Integration of Molecular Biology Advances into Oncology Clinical practice

## Friday 3<sup>rd</sup> December 2021 Afternoon

13.45 - 14.00		Welcome – <b>Ahmad Awada</b> (Bordet) & <b>Sylvie Rottey</b> (BSMO)
14.00 – 15.00 Chair : A. Awada	14.00 – 14.20	Towards a high performance Belgian Oncology Research System – <b>R. Mellaerts</b> (Fondation Roi Baudouin)
	14.20 – 14.40	An introduction to decentralized and virtual clinical trials : the spiderweb project - <b>N. Kotecki</b> (IJB)
	14.40 – 15.00	A new framework for access to molecular-guided treatments in Belgium : GENE0 & Ballet – <b>K. Punie</b> (UZ Leuven)
15.00 – 15.40 Chair : S. Rottey	15.00 – 15.20	Antibody drugs conjugates in solid tumors : A welcome therapeutic strategy – <b>E. Coquan</b> (Caen)
	15.20 – 15.40	Radionuclide therapy in solid tumors – <b>T. Lahoutte</b> (UZ Brussel)
15.40 – 16.30		<i>News from the Industry</i>
16.30 – 17.30 Chair : M. Ignatiadis	16.30 – 16.50	Neoadjuvant immunotherapy: Rationale and emerging data – <b>J. Kerger</b> (IJB)
	16.50 – 17.10	New Immunotherapy strategies in melanoma beyond PD1 inhibitors– <b>O. Bechter</b> (UZLeuven)
	17.10 – 17.30	Sarcoma: Insights in biology and new therapies – <b>N. Penel</b> (Lille)
17.30 – 17.45		Pfizer Oncology Award – Winner 2021 – <b>Sylvie Rottey</b> (UZ Gent)
17.45 – 18.15 Chair : J. Collignon	17.45 – 18.00	Esophageal and GEJ tumors: New therapies changing practice – <b>J. Collignon</b> (CHU Liège)
	18.00 – 18.15	Biology and new therapies in colorectal cancer – <b>D. Papamichael</b> (Cyprus)

# 15<sup>th</sup> BSMO-Bordet Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice

## *Saturday 4<sup>th</sup> December 2021 Morning*

<p><b>8.30 – 9.10</b> Chair : M. Brandao</p>	<p>08.30 – 08.50 08.50 – 09.10</p>	<p>Emerging biomarkers in immuno-oncology – <b>H. Prenen</b> (UZA) Biological agents in resistant tumors to first generation drugs in NSCLC – <b>G. Berchem</b> (Luxembourg)</p>
<p><b>9.10 – 9.50</b> Chair : W. Lybaert</p>	<p>09.10 – 09.30 09.30 – 09.50</p>	<p>Advanced cervical cancer : current treatments and future strategies– <b>C. Gennigens</b> (CHU Liège) Head and neck virus-induced cancer: Management in 2021 –<b>C. Le Tourneau</b> (Institut Curie – Paris)</p>
<p><b>10.00 – 10.30</b></p>		<p><i>News from the Industry</i></p>
<p><b>10.30 – 11.10</b> Chair : TBC</p>	<p>10.30 – 10.50 10.50 – 11.10</p>	<p>Bladder cancer preservation strategies – <b>P. Barthélémy</b> (Strasbourg) Therapeutic algorithm in RCC : from adjuvant to advanced disease – <b>S. Rottey</b> (UZ Gent)</p>
<p><b>11.10 – 12.20</b> Chair : C. Duhem</p>	<p>11.10 – 11.30 11.30 – 11.50 11.50 – 12.20</p>	<p>Mutated breast cancer beyond BRCA: management in 2021 – <b>F. Duhoux</b> (UCL) Immunotherapy and breast cancer : implication for clinical practice – <b>A. Gonçalves</b> (Marseille) Therapeutic strategies changing clinical practice and emerging in breast cancer – <b>A. Awada</b> (IJB)</p>
<p><b>12.20 – 12.30</b></p>		<p>Conclusions</p>